Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders

References

• Gaulard P, Swerdlow SH, Harris NL, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2017. p. 462–464.
   Google Scholar
• Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317–1321.
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Hanasono MM, et al. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma. 1995;16:363–368.
   PubMed Web of Science ®Google Scholar
• Rizzi R, Curci P, Delia M, et al. Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2009;26:1–9.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Meynard JB, Auger I, et al. Epstein–Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003;48:1223–1228.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Tomita Y, Zhiming D, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer. 2004;108:443–449.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82:1106–1109.
   PubMed Web of Science ®Google Scholar
• Hasserjian RP, Chen S, Perkins SL, et al. Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol. 2009;22:1532–1540.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci. 2010;101:1309–1313.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012;53:616–623.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–28.
   PubMed Web of Science ®Google Scholar
• Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014;41:293–299.
   PubMed Web of Science ®Google Scholar
• Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56:3045–3051.
   PubMed Web of Science ®Google Scholar
• Gion Y, Iwaki N, Takata K, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108:1271–1280.
   PubMed Web of Science ®Google Scholar
• Saito S, Kaneko Y, Yamaoka K, et al. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017;56:940–946.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018;59:1143–1152.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Kimura Y, Nemoto T, et al. Therapy-related myeloid neoplasm in methotrexate-associated lymphoproliferative disease in a rheumatoid arthritis patient. J Clin Exp Hematopathol. 2014;54:137–141.
   PubMedGoogle Scholar
• Kurita D, Miyoshi H, Ichikawa A, et al. Clinicopathological study of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients: histological classification and predictive factors for disease progression. ASH Meeting #4168; 2017.
   Google Scholar
• Saito S, Suzuki K, Yoshimoto K, et al. Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018;9:621.
   PubMed Web of Science ®Google Scholar
• Takanashi S, Aisa Y, Ito C, et al. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 2017;37:1629–1633.
   PubMed Web of Science ®Google Scholar
• Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28:1–8.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Tran H, Nourse J, Hall S, et al. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22:261–281.
   PubMed Web of Science ®Google Scholar
• Savoie A, Perpete C, Carpentier L, et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. 1994;83:2715–2722.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–571.
   PubMed Web of Science ®Google Scholar
• Lelièvre JD, Sacre K, Adle-Biassette H, et al. Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol. 2005;52:24–27.
   PubMed Web of Science ®Google Scholar
• Komatsuda A, Wakui H, Nimura T, et al. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008;18:315–318.
   PubMed Web of Science ®Google Scholar